Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/217223
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | A compendium answering 150 questions on COVID‐19 and SARS‐CoV‐2 |
Autor: | Riggioni, Carmen; Comberiat, Pasquale; Giovannini, Mattia; Agache, Ioana; Akdis, Mubeccel; Alves-Correia, Magna; Antó, Josep M.; Arcolaci, Alessandra; Azkur, Ahmet Kursat; Azkur, Dilek; Beken, Burcin; Boccabella, Cristina; Bousquet, Jean; Breiteneder, Heimo; Carvalho, Daniela; Vecillas, Leticia de las; Diamant, Zuzana; Eguiluz-Gracia, Ibon; Eiwegger, Thomas; Eyerich, Stephanie; Fokkens, Wytske; Gao, Ya-dong; Hannachi, Farah; Johnston, Sebastian L.; Jutel, Marek; Karavelia, Aspasia; Klimek, Ludfger; Moya, Beatriz; Nadeau, Kari C.; O'Hehir, Robin; O'Mahony, Liam; Pfaar, Oliver; Sanak, Marek; Schwarze, Jürgen; Sokolowska, Milena; Torres Jaén, María José; Veen, Willem van de; Zelm, Menno C. van; Wang, De Yun; Zhang, Luo; Jiménez Saiz, Rodrigo CSIC ORCID; Akdis, Cezmi A. | Palabras clave: | Allergy Coronavirus disease 2019 COVID-19 SARS‐CoV‐2 Severe acute respiratory syndrome–related coronavirus 2 |
Fecha de publicación: | 14-jun-2020 | Editor: | John Wiley & Sons | Citación: | Allergy (2020) | Resumen: | In December 2019, China reported the first cases of the coronavirus disease 2019 (COVID‐19). This disease, caused by the severe acute respiratory syndrome–related coronavirus 2 (SARS‐CoV‐2), has developed into a pandemic. To date, it has resulted in ~9 million confirmed cases and caused almost 500 000 related deaths worldwide. Unequivocally, the COVID‐19 pandemic is the gravest health and socioeconomic crisis of our time. In this context, numerous questions have emerged in demand of basic scientific information and evidence‐based medical advice on SARS‐CoV‐2 and COVID‐19. Although the majority of the patients show a very mild, self‐limiting viral respiratory disease, many clinical manifestations in severe patients are unique to COVID‐19, such as severe lymphopenia and eosinopenia, extensive pneumonia, a “cytokine storm” leading to acute respiratory distress syndrome, endothelitis, thromboembolic complications, and multiorgan failure. The epidemiologic features of COVID‐19 are distinctive and have changed throughout the pandemic. Vaccine and drug development studies and clinical trials are rapidly growing at an unprecedented speed. However, basic and clinical research on COVID‐19–related topics should be based on more coordinated high‐quality studies. This paper answers pressing questions, formulated by young clinicians and scientists, on SARS‐CoV‐2, COVID‐19, and allergy, focusing on the following topics: virology, immunology, diagnosis, management of patients with allergic disease and asthma, treatment, clinical trials, drug discovery, vaccine development, and epidemiology. A total of 150 questions were answered by experts in the field providing a comprehensive and practical overview of COVID‐19 and allergic disease. | Versión del editor: | https://doi.org/10.1111/all.14449 | URI: | http://hdl.handle.net/10261/217223 | DOI: | 10.1111/all.14449 | ISSN: | 0105-4538 | E-ISSN: | 1398-9995 |
Aparece en las colecciones: | (PTI Salud Global) Colección Especial COVID-19 (CNB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
66
checked on 12-mar-2024
SCOPUSTM
Citations
85
checked on 27-mar-2024
WEB OF SCIENCETM
Citations
77
checked on 26-feb-2024
Page view(s)
234
checked on 28-mar-2024
Download(s)
49
checked on 28-mar-2024
Google ScholarTM
Check
Altmetric
Altmetric
Artículos relacionados:
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.